α-MSH (11-13)
α-MSH (11-13) (ACTH-(11-13)) is a C-terminal tripeptide of α-MSH that can cross the blood-brain barrier. α-MSH (11-13) exhibits antipyretic, anti-inflammatory, and antibacterial activities. α-MSH (11-13) also exerts neuroprotective effects after traumatic brain injury by inhibiting excessive activation of microglia and reducing neuronal apoptosis. α-MSH (11-13) can be used in research related to traumatic brain injury, fever, and bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 67727-97-3
- Formula: C16H30N4O4
- Molecular Weight:342.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
α-MSH (11-13) induces MC1R-dependent calcium signaling and inhibits TNF-α-stimulated NF-κB activation in MC1R-transfected CHO-K1 cells[1].
α-MSH (11-13) inhibits the production of TNF-α, IL-6, and nitric oxide in LPS (HY-D1056)-stimulated mouse microglial cell cultures[1].
α-MSH (11-13) (0-0.1 mM; 2 h) significantly inhibits colony formation of clinical methicillin-resistant Staphylococcus aureus/Candida albicans isolates[3].
α-MSH (11-13) (1 μM; 3 min) significantly increases the level of cAMP accumulation in permeabilized Candida albicans[3].
α-MSH (11-13) (0-0.1 mM; 2 h) enhances the killing activity of human neutrophils against clinical isolates of methicillin-resistant Staphylococcus aureus and Candida albicans[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
α-MSH (11-13) (0.5-200 mg; intracerebroventricular injection, intravenous injection; single administration) dose-dependently reduces leukocytic pyrogen-induced fever in rabbits after central or peripheral administration[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57Bl/6N (2-month-old male, 21-35 g, traumatic brain injury induced via controlled cortical impact)[1]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced secondary brain contusion volume by 24%.
Decreased microglial activation.
Lowered number of apoptotic neurons.
Did not significantly change neurological severity score.
-
Animal Model:New Zealand white (adult)[2]
-
Dosage:0.5 mg (i.c.v.); 1.0 mg (i.c.v.); 2.0 mg (i.c.v.); 2 mg (i.v.); 20 mg (i.v.); 200 mg (i.v.)
-
Administration:i.c.v.; single dose; i.v.; single dose
-
Result:Produced average percent reductions of the area under the control fever curve (over 1.5 hr) of 24% (0.5 mg i.c.v.), 31% (1.0 mg i.c.v.), and 48% (2.0 mg i.c.v.), with each dose significantly more antipyretic than lower doses.
Produced average percent reductions of the area under the control fever curve (over 1.5 hr) of 34% (2 mg i.v.), 27% (20 mg i.v.), and 67% (200 mg i.v.).
Had no effect on body temperature when 200 mg i.v.
dose was administered to afebrile rabbits.
Chemical Information
-
CAS No. 67727-97-3
-
Molecular Weight 342.43
-
Formula C16H30N4O4
-
Synonyms
ACTH-(11-13); Lys-Pro-Val; H-Lys-Pro-Val-OH
-
Sequence
Lys-Pro-Val
-
Sequence Shortening
KPV
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
[1]. Schaible EV, et al. Single administration of tripeptide α-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice. PLoS One. 2013;8(8):e71056. Published 2013 Aug 5. [Content Brief]
[2]. Richards DB, et al. Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit. Peptides. 1984;5(4):815-817. [Content Brief]
[3]. Cutuli M, et al. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000 Feb;67(2):233-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)